Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Jonat

Showing results (101-110 of 108) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 108 results.
International Journal of Cancer|April 20, 2004
Limited relevance of the CHEK2 gene in hereditary breast cancerMichael R Dufault, Beate Betz, Barbara Wappenschmidt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2009
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancerJosé Baselga, Vladimir Semiglazov, Peter van Dam, et al.
Oncotarget|April 25, 2015
TRAIL-R2 promotes skeletal metastasis in a breast cancer xenograft mouse modelHendrik Fritsche, Thorsten Heilmann, Robert J Tower, et al.
Breast Cancer Research and Treatment|July 6, 2012
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancerMartin Schuler, Ahmad Awada, Philipp Harter, et al.
Breast Care (Basel, Switzerland)|November 5, 2010
Zurich Consensus: German Expert Opinion on the St. Gallen Votes on 15 March 2009 (11th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer)Matthias W Beckmann, Jens-Uwe Blohmer, Serban-Dan Costa, et al.
European Journal of Cancer (Oxford, England : 1990)|September 22, 2018
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2Mario Campone, Seock-Ah Im, Hiroji Iwata, et al.
The Lancet. Oncology|June 4, 2017
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trialJosé Baselga, Seock-Ah Im, Hiroji Iwata, et al.
Breast Care (Basel, Switzerland)|January 14, 2014
13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013)Michael Untch, Bernd Gerber, Nadia Harbeck, et al.
Pageof 11

Showing results (101-110 of 108) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 108 results.
International Journal of Cancer|April 20, 2004
Limited relevance of the CHEK2 gene in hereditary breast cancerMichael R Dufault, Beate Betz, Barbara Wappenschmidt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2009
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancerJosé Baselga, Vladimir Semiglazov, Peter van Dam, et al.
Oncotarget|April 25, 2015
TRAIL-R2 promotes skeletal metastasis in a breast cancer xenograft mouse modelHendrik Fritsche, Thorsten Heilmann, Robert J Tower, et al.
Breast Cancer Research and Treatment|July 6, 2012
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancerMartin Schuler, Ahmad Awada, Philipp Harter, et al.
Breast Care (Basel, Switzerland)|November 5, 2010
Zurich Consensus: German Expert Opinion on the St. Gallen Votes on 15 March 2009 (11th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer)Matthias W Beckmann, Jens-Uwe Blohmer, Serban-Dan Costa, et al.
European Journal of Cancer (Oxford, England : 1990)|September 22, 2018
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2Mario Campone, Seock-Ah Im, Hiroji Iwata, et al.
The Lancet. Oncology|June 4, 2017
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trialJosé Baselga, Seock-Ah Im, Hiroji Iwata, et al.
Breast Care (Basel, Switzerland)|January 14, 2014
13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013)Michael Untch, Bernd Gerber, Nadia Harbeck, et al.
Pageof 11